knowledge -WSS

knowledge

author：knowledge 2025-08-12 09:13:33 - browse：9459

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： FDA early review: GLP

explore

WSS

Nonprofit, backed by Microsoft, to certify AI tools in health care

At JPM 2024, hospital systems pitch financial strength to investors

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Medicare Advantage overpayments discussion gets experts fired up

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Wikipedia

knowledge

hotspot

Cancer drug shortages should be causing more outrage

FDA early review: GLP

Activists slam private health insurers over coverage restrictions

There's no autism epidemic. It's an autism diagnosis epidemic

Bright Health sells Medicare Advantage business to Molina

Allen Institute goes after foundational questions, CEO Costa says

Malaria cases in Florida and Texas: Here’s what you need to know

Why the world’s most expensive drug might be worth the price

Supreme Court strikes down use of affirmative action

Decaf coffee targeted by food safety group under obscure FDA rule

hotspot

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

American taxpayers paid $1.8 trillion in health care costs in 2022

States should stop sabotaging methadone treatment reform

Vertex Pharmaceuticals may move headquarters in Boston

Ascension's ugly legal battle over care for poor patients in Texas

Abortion pill Supreme Court ruling could impact entire drug industry

leisure time

hotspot

explore

focus